BridgeBio's Oral Infigratinib Shows Reduced Sleep Apnea And Ear Infection Rates Beyond Growth Benefits In Phase 3 PROPEL 3 Trial At 52 Weeks
- Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media eventsStabilization of sleep